Related references
Note: Only part of the references are listed.Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection
J. Ambrosioni et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
Isabelle Malet et al.
MBIO (2017)
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro
Francesco Saladini et al.
AIDS (2017)
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study
Danielle P. Porter et al.
HIV CLINICAL TRIALS (2016)
G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance
Soundasse Munir et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'
Corinne Amiel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses
S. Lambert-Niclot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen
Jade Ghosn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Raltegravir, elvitegravir, and metoogravir: the birth of me-too HIV-1 integrase inhibitors
Erik Serrao et al.
RETROVIROLOGY (2009)
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
Isabelle Malet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Share Paper
